HOIST

Hoist Therapeutics is an early-stage biotechnology company dedicated to developing novel therapies for muscle-wasting conditions and skeletal muscle dysfunction. Founded in 2023 by Tariq Kassum, a former executive at MyoKardia and Celsius Therapeutics, the company focuses on addressing significant unmet medical needs in populations suffering from sarcopenia and cancer cachexia. Hoist leverages deep expertise in muscle biology to identify and develop small molecule candidates designed to restore muscle mass and physical function. The company is currently building its initial pipeline through internal research and the strategic acquisition of development-stage assets. Hoist aims to improve patient outcomes by targeting the biological drivers of muscle loss associated with aging and chronic illness.